Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

DIMERIX LIMITED

INVESTOR PRESENTATION - DIMERIX LIMITED

ASX:DXB

DIMERIX LIMITED

Health Care

Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.

Read more

Market Cap

56.36m

Price at Close

$0.285

4w avg. Volume

2.45m

4w avg. Turnover

$747.15k

Announcements
announcementt+2 movementdate
  • Receipt of R&D Tax Incentive

    Progress Report · Market sensitive

  • -

    20 Oct 2020

-

20 Oct 2020
  • Shareholder Update

    Progress Report

  • -

    19 Oct 2020

-

19 Oct 2020
  • DMX-700 Data Demonstrates Effect on Key COPD Receptors

    Progress Report · Market sensitive

  • +3.39%

    06 Oct 2020

+3.39%

06 Oct 2020
  • Amended Constitution

    Company Administration

  • -1.64%

    30 Sep 2020

-1.64%

30 Sep 2020
  • Results of Meeting

    Notice Of Meeting

  • -1.64%

    30 Sep 2020

-1.64%

30 Sep 2020
  • AGM Presentation

    Periodic Reports

  • -1.64%

    30 Sep 2020

-1.64%

30 Sep 2020
  • CEO's Address to Shareholders

    Chairman's Address

  • -1.64%

    30 Sep 2020

-1.64%

30 Sep 2020
  • Virtual Meeting Voting and Registration Guide

    Notice Of Meeting

  • -13.70%

    29 Sep 2020

-13.70%

29 Sep 2020
  • Notification of expired Options

    Issued Capital

  • +13.95%

    24 Sep 2020

+13.95%

24 Sep 2020
  • Investor Presentation

    Periodic Reports

  • -5.45%

    13 Sep 2020

-5.45%

13 Sep 2020
Market Data

Current Price

$0.285

52WK HIGH

$0.78

52WK LOW

$0.105

1YR RETURN

+147.83%

1YR RETURN VS. SECTOR

+121.10%

90 DAY RETURN

-18.57%

ASX RANK

1,017

/2,008

SECTOR RANK

26

/47

SHARES OUTSTANDING

197.75m
ASX:DXB

DIMERIX LIMITED

Health Care

Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.

Read more

Market Cap

56.36m

Price at Close

$0.285

4w avg. Volume

2.45m

4w avg. Turnover

$747.15k

ASX:DXB is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.